Oral berberine added to conventional heart-failure therapy,
does it really help with Reduction of all-cause mortality in chronic congestive heart failure?
research showsGrade C with 50 points. Over a mean 24 months, 7/79 berberine recipients and 13/77 placebo recipients died, with the paper reporting P<.02. However, no hazard ratio or 95% CI is available, and prespecification, allocation concealment, and follow-up completeness are unverified, so the event counts do not establish a precise effect.
ads claimIt cannot be advertised as established survival therapy, an antiarrhythmic replacement, or halving mortality risk.
Useful facts when choosing a product
- This verdict applies only to the displayed formulation, route, dose, duration, population, endpoint, and comparator.
- Berberine hydrochloride, botanical extracts, combination formulas, dihydroberberine, other derivatives, and topical products are not interchangeable.
- Warning. High-dose use in heart failure or arrhythmia must not be attempted without medical supervision. Bradycardia, hypotension, interactions, electrolytes, renal function, and liver status require separate review.
Chamgap Semantic Classification Code
Permanent code issued
S.berberine.oral-addon.all-cause-mortality.reduce.placeboSupplements and nutraceuticals > Berberine (exact salt form unverified) > Oral add-on > Chronic heart-failure all-cause mortality > Reduction claim > Placebo plus then-standard care
Bound to the mean-24-month all-cause mortality signal; LVEF, arrhythmia, and six-minute walk are separate, with no transfer to modern heart-failure care. The code identifies the intervention and claim; it never contains the evidence grade, score, or safety result.
Exact Claim Classification
These independent facets prevent evidence from different forms, routes, populations, effects, and comparators from being mixed.
| Intervention class | S · Supplement or nutraceutical |
|---|---|
| Canonical ingredient or intervention | Berberine |
| Source or part used | Exact salt form, source plant, and product unverified |
| Formulation or processing | Oral adjunctive berberine; exact formulation unverified |
| Route | Oral add-on |
| Dose | 1.2-2.0 g/day |
| Duration | Eight-week treatment assessment and mean 24-month follow-up |
| Population | 156 heart-failure patients with ischemic or idiopathic dilated cardiomyopathy and ventricular ectopy or nonsustained VT |
| Effect or condition | Lower all-cause mortality |
| Primary endpoint | All-cause death over a mean 24-month follow-up |
| Comparator | Placebo plus then-conventional heart-failure therapy |
| Duplicate-detection key | Berberine|Oral adjunctive berberine; exact formulation unverified|Oral add-on|156 heart-failure patients with ischemic or idiopathic dilated cardiomyopathy and ventricular ectopy or nonsustained VT|Lower all-cause mortality|Eight-week treatment assessment and mean 24-month follow-up |
What the research actually shows
The original abstract and bibliographic record plus retraction, concern, and correction status were checked; event counts were not transferred to modern standard care.
Why this is classified as C (50)
Axes are H/R1/I1/EX/B2/CX. H is one strength, but fewer than 200 participants, uncertain allocation/analysis integrity, and an unquantified effect yield C/50.
Counterpoint. The hard-endpoint direction matters, but reporting is incomplete and no independent confirmatory mortality trial was identified.
Rejudgment record. Independent Codex cross-check — One formulation, route, population, claim, principal endpoint, and comparator
| Endpoint | H | Hard endpoint - actual events such as death |
| Replication | R1 | Single confirmatory trial |
| Independence | I1 | Mixed funding sources |
| Effect size | EX | The clinical size of the effect could not be judged |
| Precision | CX | No pooled confidence interval could be confirmed |
The scoring table and the verdict agree (C).
Cross-check — AI research and Codex final gate
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Efficacy and safety of berberine for congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy | Design, allocation, masking, endpoint hierarchy, and analysis set were independently checked. | 77 | Funding, product support, employee authorship, and conflicts were assessed separately. | The principal endpoint contract is preserved; other outcomes remain separate. | Verified estimates are preserved; missing confidence intervals were not invented. | Evidence weight reflects directness, formulation match, hierarchy, and reporting limitations. |
Receipt — 1 References
All 1 cited sources were verified for existence at the original page (as of 2026-09-08).
Final verification and publication gate: Codex · Verification cutoff: 2026-09-08 · Corrections: none
Cite this verdict
[Chamgap] Adjunctive Berberine for Chronic Heart-Failure Mortality—A 7-versus-13 Death Signal With Incomplete Survival Estimates From an Old 156-Person Trial — Evidence Grade C·50. 1 cited sources checked. Source: https://chamgap.com/en/verdicts/heart/adjunctive-berberine-chronic-heart-failure-all-cause-mortality/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.